Acrivon Therapeutics, Inc. ACRV
Set alert
At close
Pre-market · Nov 3, 6:29 AM ET
- YTD
- -33.20%
- 1 year
- -19.10%
- Open
- 1.66
- Prev close
- 1.66
- Mkt cap
- 68.99M
- Vol
- 228.22K
- Avg vol
- 294.81K
- EPS
- -1.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.58
- High
- 1.71
- Forward P/E
- -2.31
- Beta
- 0.00
- Short ratio
- 15.38
- Inst. own
- 75.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 7.44
- 200-d avg
- 7.65
- 1y target
- 21.11
News
-
5 days ago benzinga.com
Acrivon Therapeutics To Present Dose Escalation Data From Its Current Phase 1/2 Trial Of ACR-2316 At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical-stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
5 days ago globenewswire.com
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 Durable…
-
2 weeks ago benzinga.com
Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027
ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft modelsPrioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…
-
2 months ago benzinga.com
Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of…
-
3 months ago benzinga.com
Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a yearOral weekly…
-
3 months ago benzinga.com
Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24
Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug DiscoveryPresenter: Lei…
-
5 months ago benzinga.com
Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of…
-
6 months ago benzinga.com
Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
-
7 months ago benzinga.com
Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses…
-
7 months ago benzinga.com
Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates…
-
9 months ago benzinga.com
Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8
Piper Sandler analyst Edward Tenthoff maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $6 to $8.
9 months ago benzinga.com
Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls
Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, and pipeline progress, while confirming cash runway into 2027.
9 months ago benzinga.com
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
9 months ago benzinga.com
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
-
9 months ago benzinga.com
Market-Moving News for January 8th
ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates ACRV: 38% | Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial…
-
9 months ago benzinga.com
Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial Clinical Data From ACR-2316 Phase 1 Trial, Nominates Next AP3-Enabled Preclinical Development Candidate ACR-6840
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
9 months ago benzinga.com
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
10 months ago benzinga.com
Acrivon Therapeutics to Release New Cancer Drug Data on Jan. 8
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
2 years ago benzinga.com
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
-
2 years ago benzinga.com
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 311 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 127 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 220 stocks hit new 52-week lows.